ERBB2 and neoplasm: To determine whether our linker‐drug technology may be clinically applicable and thus potentially address one of the most critical limitations of existing HER2‐ADCs, the in vivo efficacy of our LCB‐ADCs was evaluated in patient‐derived xenograft (PDX) tumor models, which were considered to be the most relevant model for patients.[36] PDX models prepared with human GC tissues in which HER2 expression was relatively high (HER2 +++ GC PDX) or low (HER2 ++ GC PDX)[37] were treated with T‐DM1 or LCB‐ADCs (Figure6a,b).